AVEO: AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist

(marketscreener.com) BOSTON, Feb. 06, 2024 -- AVEO Oncology, an LG Chem company , today announced The Oncologist has published a post-hoc analysis of long-term progression free survival, overall survival and safety data from the Phase 3 TIVO-3 trial evaluating FOTIVDA® in patients with relapsed or refractory advanced renal cell carcinoma . In the...https://www.marketscreener.com/quote/stock/AVEO-PHARMACEUTICALS-INC-50916923/news/AVEO-Oncology-Announces-Publication-of-Long-Term-Survival-in-Patients-With-Relapsed-Refractory-Advan-45892904/?utm_medium=RSS&utm_content=20240206